Dr. Nanhai G. Chen is the Founder and Chief Executive Officer of ViroMissile, Inc., a biotechnology company focused on the development of next-generation oncolytic immunotherapies. He holds a Ph.D. in Molecular Virology and has over thee decades of experience in virology, cancer research, translational medicine, and drug development. Dr. Chen’s work integrates virology, immuno-oncology, and targeted therapies to create innovative treatments for solid tumors. His leadership has driven multiple programs from preclinical discovery into early-phase clinical development, with a strong emphasis on addressing unmet needs in oncology.